TAMPA, Fla., Oct. 4 /PRNewswire-FirstCall/ -- Nanobac Life Sciences, Inc.
(OTCPK: NNBP) is pleased to announce the signing of a Manufacturing Agreement
with Medicorp, Inc., for the production of two blood tests for the detection
of Nanobacteria. Nanobac is transferring production of both the Nano-Capture
ELISA assay and the Nano-Sero IgG ELISA assay from its Nanobac Oy research
laboratory in Kuopio, Finland to Medicorp in preparation for FDA clinical
trials and expanded distribution. Medicorp is Canada's largest, independent
ISO 9001-certified manufacturer and distributor of immunodiagnostic and
"We are pleased to be able to work with Medicorp to scale-up production of
our test kits in preparation for FDA clinical trials and for our distribution
of our test kits outside the U.S., commented John Stanton, Nanobac's President
and Chief Executive Officer. "This move prepares us for increased production
of our test kits in an ISO-9001-certified manufacturing facility. This is a
key step for the Company as we move from a research oriented company to one
that rapidly develops and commercializes products."
Nanobac has already signed a distribution agreement with Oxoid Ltd. for
territories in Europe, Brazil and Australia. Oxoid is one of the world's
leading manufacturers and distributors of microbiological culture media and
other diagnostic products. With corporate headquarters in Basingstoke,
Hampshire, Oxoid Ltd is supported by a network of wholly owned sales and
distribution companies in Europe, North and South America and Australia.
Nanobac recently announced that an abstract entitled "Increased serum
levels of Nanobacteria antibodies are associated with high coronary
calcification score" has been accepted for presentation in an oral session at
the American Heart Association (AHA) Scientific Sessions 2004 conference in
New Orleans, LA, Nov 7-10, 2004. The research was performed by Stephen
Epstein, MD and Jianhui Zhu, PhD at the Washington Hospital Center,
Nanobacterium sanguineum (nanobacteria) is the smallest self-replicating
organism ever detected -- at 50 to 500 billionths of a meter, 1/100th the size
of the smallest previously known bacteria. Nanobacteria have been implicated
in a variety of human diseases associated with pathological calcification.
Nanobacteria were first discovered in 1988 by a Finnish researcher, and
Nanobac OY co-Founder Olavi Kajander, M.D., Ph.D. Medical microbiologist Neva
Ciftcioglu, Ph.D. joined his team in 1991 and their corroborated work with
nanobacteria over the past 13 years has put them at the forefront of research
into this medically important pathogen. Their research established that the
blood-borne nanobacteria forms slow-growing calcified colonies in arteries and
Nanobac has identified two biomarkers of nanobacterial infection. These
tests are being developed as the NB2 test, which is composed of the
nanobacteria antigen test, and the nanobacteria IgG antibody test.
About Nanobac Lifesciences
Nanobac Life Sciences, Inc. is dedicated to improving people's health
through the detection and eradication of Nanobacterium sanguineum
(nanobacteria). The Company's pioneering research is establishing the
pathogenic role of nanobacteria in calcification, particularly in coronary
artery heart disease and vascular disease. Nanobac has identified two
biomarkers of nanobacterial infection, and expects to file for FDA approval of
its NB2(TM) ELISA assays to detect nanobacterial antigen and IgG antibody. It
is also leveraging its proprietary knowledge and intellectual property to
develop the first FDA approved therapeutic to detect and treat nanobacterial
infection. The Company currently markets, through its wholly owned subsidiary,
Nanobac Sciences, a patented nanobiotic regimen that it developed.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more
information, please visit our website at: www.nanobaclifesciences.com.
MEDICORP is Canada's largest, independent ISO 9001-certified manufacturer
and distributor of immunodiagnostic and microbiology products. MEDICORP
manufactures and markets state-of-the-art immunoassay products, Monoclonal
Antibodies for Neuroscience and a broad line of Polyclonal Antibodies to
Peptide and Steroid hormones in Canada and through distributors in Europe and
Asia. MEDICORP's Free PSA [fPSA] assay has revolutionized the differential
diagnosis of prostate cancer.
Investors are cautioned that certain statements contained in this document
as well as some statements in periodic press releases and some oral statements
of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements"
within the meaning of the Private Securities Litigation Reform Act of 1995
(the "Act). Forward-Looking statements include statements which are predictive
in nature, which depend upon or refer to future events or conditions, which
include words such as "believes," "anticipates," "intends," "plans,"
"expects," and similar expressions. In addition, any statements concerning
future financial performance (including future revenues, earnings or growth
rates), ongoing business strategies or prospects, and possible future Nanobac
Life Sciences, Inc. actions, which may be provided by management, are also
forward-looking statements as defined by the Act. Forward-Looking statements
involve known and unknown risks, uncertainties, and other factors which may
cause the actual results, performance or achievements of the Company to
materially differ from any future results, performance or achievements
expressed or implied by such forward-looking statements and to vary
significantly from reporting period to reporting period. Although management
believes that the assumptions will, in fact, prove to be correct or that
actual future results will not be different from the expectations expressed in
this report. These statements are not guarantees of future performance and
Nanobac Life Sciences, Inc. has no specific intention to update these
For more information contact:
John Stanton or Alex Edwards
Nanobac Life Sciences, Inc.
Cynthia Isaac, PhD
The Ruth Group
SOURCE Nanobac Life Sciences, Inc.